Semarion raised $3.8 million to scale its cell assay technology for drug discovery. The company’s SemaCyte platform is designed to convert adherent cell models into assay-ready, barcoded reagents, aiming to make screening workflows more scalable while improving data depth. The investment signals continued focus on workflow automation and assay standardization as a bottleneck in early drug discovery. Semarion’s approach addresses the operational friction of handling adherent cells at scale by packaging them in a more consistent, higher-throughput format. As competition for novel assay modalities grows, investors will watch whether SemaCyte demonstrates reproducibility across targets and expands into broader screening categories.